Program
Mesenchymal Stem Cell
Also written as “Mesenchymal stem cell”, “mesenchymal stem cell” and “Mesenchymal Stem Cell Injection”.
Its studies are mostly in COVID-19 · Osteoarthritis, Knee · Myocardial Ischemia · Osteoarthritis · Acquired Immunodeficiency Syndrome, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Rohto Pharmaceutical | 41 open or running | phase 2since Aug 3, 2017 | Aug 3, 2017 | Sep 30, 2028phase 2 · NCT07192211 |
| Azidus Brasil | 10 open or running | phase 2since Mar 18, 2020 | Mar 18, 2020 | none ahead |
| CAR-T (Shanghai) Biotechnology | 10 open or running | early phase 1since Oct 11, 2019 | Oct 11, 2019 | none ahead |
| Cell Energy Life Sciences Group | 11 open or running | phase 2since May 15, 2023 | May 15, 2023 | Jul 10, 2027phase 2 · NCT05939167 |
| Meluha Life Sciences SDN BHD | 10 open or running | phase 2since Aug 17, 2020 | Aug 17, 2020 | none ahead |
| Pharmicell | 10 open or running | phase 1since Jan 13, 2015 | Jan 13, 2015 | none ahead |
| Tianjin Weikai Bioeng. | 10 open or running | phase 2since Feb 18, 2019 | Feb 18, 2019 | none ahead |
| TricelX | 11 open or running | phase 2since Mar 17, 2026 | Mar 17, 2026 | May 2027phase 2 · NCT07487766 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2015First study: phase 1 study in Erectile DysfunctionNew to PharmicellPharmicell · NCT02344849 · 10 enrolled · Korea, Republic of
- Aug 3, 2017Rohto Pharmaceutical's first study: phase 2 study in Decompensated Liver CirrhosisNew to Rohto PharmaceuticalRohto Pharmaceutical · NCT03254758 · 21 enrolled · Japan
- Feb 18, 2019Tianjin Weikai Bioeng.'s first study: phase 2 study in Acute-On-Chronic Liver FailureNew to Tianjin Weikai Bioeng.Tianjin Weikai Bioeng. · NCT03863002 · 45 enrolled · China
- Oct 11, 2019CAR-T (Shanghai) Biotechnology's first study: early phase 1 study in Osteoarthritis, KneeNew to CAR-T (Shanghai) BiotechnologyCAR-T (Shanghai) Biotechnology · NCT04130100 · 60 enrolled · China
- Mar 18, 2020Azidus Brasil's first study: phase 2 study in COVID-19 PneumoniaNew to Azidus BrasilAzidus Brasil · NCT04315987 · 90 enrolled · Brazil
- Aug 17, 2020Meluha Life Sciences SDN BHD's first study: phase 2 study in Osteoarthritis, KneeNew to Meluha Life Sciences SDN BHDMeluha Life Sciences SDN BHD · NCT04520945 · 100 enrolled · Malaysia
- Aug 20, 2020Phase 1 study in Severe Acute Respiratory Syndrome Coronavirus 2Rohto Pharmaceutical · NCT04522986 · 6 enrolled · Japan
- May 9, 2021Phase 2 study in SARS-CoV-2 Infection( COVID-19 )Rohto Pharmaceutical · NCT04888949 · 15 enrolled · Japan
- May 15, 2023Cell Energy Life Sciences Group's first study: phase 2 study in Acquired Immunodeficiency SyndromeNew to Cell Energy Life Sciences GroupCell Energy Life Sciences Group · NCT05939167 · 150 planned · China
- Aug 28, 2025Phase 2 study in Myocardial IschemiaRohto Pharmaceutical · NCT07192211 · 50 planned · Japan
- Mar 17, 2026TricelX's first study: phase 2 study in OsteoarthritisNew to TricelXTricelX · NCT07487766 · 75 planned · United States
Ahead
- May 2027Primary completion: phase 2 study in OsteoarthritisTricelX · NCT07487766
- Jul 10, 2027Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeCell Energy Life Sciences Group · NCT05939167
- Sep 30, 2028Primary completion: phase 2 study in Myocardial IschemiaRohto Pharmaceutical · NCT07192211
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07487766Osteoarthritis · United States | 2 | Not yet recruiting | TricelX | May 2027 | 75 |
| NCT07192211Myocardial Ischemia · Japan | 2 | Recruiting | Rohto Pharmaceutical | Sep 30, 2028 | 50 |
| NCT05939167Acquired Immunodeficiency Syndrome · China | 2 | Recruiting | Cell Energy Life Sciences Group | Jul 10, 2027 | 150 |
| NCT04888949SARS-CoV-2 Infection( COVID-19 ) · Japan | 2 | Completed | Rohto Pharmaceutical | May 18, 2023 | 15 |
| NCT04522986Severe Acute Respiratory Syndrome Coronavirus 2 · Japan | 1 | Completed | Rohto Pharmaceutical | Feb 2, 2021 | 6 |
| NCT04520945Osteoarthritis, Knee · Malaysia | 2 | UNKNOWN | Meluha Life Sciences SDN BHD | Sep 30, 2021 | 100 |
| NCT04315987COVID-19 Pneumonia · Brazil | 2 | Completed | Azidus Brasil | Feb 28, 2021 | 90 |
| NCT04130100Osteoarthritis, Knee · China | Early 1 | UNKNOWN | CAR-T (Shanghai) Biotechnology | Sep 30, 2021 | 60 |
| NCT03863002Acute-On-Chronic Liver Failure · China | 2 | UNKNOWN | Tianjin Weikai Bioeng. | Oct 1, 2021 | 45 |
| NCT03254758Decompensated Liver Cirrhosis · Japan | 2 | Completed | Rohto Pharmaceutical | Apr 13, 2023 | 21 |
| NCT02344849Erectile Dysfunction · Korea, Republic of | 1 | Completed | Pharmicell | Jan 31, 2018 | 10 |
How it is read
Names in the registry
- “Mesenchymal stem cell”, 4 entries
- “mesenchymal stem cell”, 2 entries
- “Mesenchymal Stem Cell Injection”, 1 entry
- “NestaCell®”, 1 entry
- “Chondrogen”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 2 studies
- Osteoarthritis, Knee, 2 studies
- Myocardial Ischemia, 1 study
- Osteoarthritis, 1 study
- Acquired Immunodeficiency Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.